MESOTHELIOMA NEWS ARCHIVE - Aug through Dec 2007

Mining Company Supports Mesothelioma Study
Funding Problems Could Affect Iron Range Study
Funding Problems Could Stall Oregon Cleanup
Par unit buys licensing rights for malignant mesothelioma drug from Alfacell.
New Technology For Cancer Screening Listens For The Signs Of Cancer: Researchers create an acoustic sensor that can report the presence of small amounts of mesothelin
W.R. Grace & Co. Lose Latest Appeals
EPA to Test New Asbestos Removal Method on Vacant Apartment Building
New Analysis of Minnesota Miners Raises More Questions
US Occupational Injury Rates Lower
EPA to Reevaluate Factory Sites
Ban Asbestos in America Act of 2007 passes Senate
Alfacell Updates Status Of ONCONASE(R) Phase III Clinical Program: Company has planned schedule for the potential completion of the final sections of its ONCONASE rolling NDA submission
Alfacell's Awkward Wait: Onconase (®) is in its final phase 3 trial for treatment of patients with unresectable malignant mesothelioma
Data Affirm Benefit of ALIMTA(®) for Patients With Malignant Pleural Mesothelioma: Alimta(®)-based regimens support patients with devastating disease
New diagnostic tool for mesothelioma to be developed: The test will extract microRNAs from a simple blood draw
Potential Preventative Action of Ranpirnase: ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma
The Barbara Ann Karmanos Cancer Institute announces significant scientific findings related to Malignant Mesothelioma: Pathway for Treatment of Malignant Pleural Mesothelioma
Workers Begin Final Cleanup at Former Asbestos Factory
Alviso to Undergo Further EPA Testing
Mild Hyperthermia Enhances Antitumor Effects of Ranpirnase: In vitro studies show hyperthermia enhances the therapeutic effects of Onconase in treatment of mesothelioma
Study shows Mesomark effective for monitoring Mesothelioma: NYU Study Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring An Asbestos-Linked Cancer
FDA Grants Orphan Drug status to Onconase for Mesothelioma: First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable Malignant Mesothelioma
FDA Approves MESOMARK® Assay for the Management of Mesothelioma Patients: First in-vitro test for mesothelioma will enable doctors to more accurately detect recurrence and monitor treatment of patients
Dallas Screening Results Reveal Asbestos Diseases
West Dallas Residents Get Asbestos Screening

**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376